filmov
tv
Using AI and Software to Accelerate Discovery, Diagnosis, and Treatment of Rare Disease Patients
Показать описание
Vikram Batra is a senior leader in Axtria’s Decision Science practice. In this podcast, we discuss how AI and software is accelerating discovery, diagnosis and treatment of rare diseases. We understand how the industry is shifting towards rare diseases, the challenges and how pharma leaders deal with them. Vikram then discusses the role of AI/ML in helping to solve patient diagnosis and the value it brings to the stakeholders. Tune in as we speak about the importance of pharma leaders investing in relevant data sets and why an accelerating speed of diagnosis is a win-win for all.
IN THIS EPISODE:
[02:50] How the industry is shifting towards rare diseases and what it means in the long run.
[04:55] Rare diseases are a completely new paradigm in context to blockbusters and traditional drugs. Vikram describes these challenges and how pharma leaders can deal with them.
[07:50] Rare diseases are unique; there needs to be a very connected approach for tackling this complexity.
[11:50] How AI/ML is helping solve the patient diagnosis problem.
[15:00] Key takeaways from Vikram’s discussion
KEY TAKEAWAYS:
People suffering from these rare diseases spend between five to seven years before receiving a correct diagnosis. Having a good understanding of the patient journey in rare diseases is critical. Pharma leaders must invest in relevant data sets and build the required infrastructure for new models that leverage AI/ML. Accelerating the speed of diagnosis is a win-win for all.
LINKS MENTIONED:
Vikram Batra on LinkedIn:
BIO:
Vikram is a senior leader in Axtria’s Decision Science practice with over 20 years of analytics, consulting and leadership experience. He has worked on both ends of the spectrum – working for large pharma as well as a long tenure as a management consultant. Vikram has a proven track record of addressing challenging strategic issues for pharmaceutical customers and helping them with comprehensive solutions across brand strategy, sales operations, and market access. He has built, coached and led diverse analytics teams that successfully deliver insights using advanced data analytics and AI. His experience spans across global markets including Top 5 EU, Australia, Canada, and other geographies.
Before joining Axtria, Vikram held roles of increasing responsibility and leadership at MarketRx, Sanofi, Information Resources (IRI) and Health Products Research (HPR).
IN THIS EPISODE:
[02:50] How the industry is shifting towards rare diseases and what it means in the long run.
[04:55] Rare diseases are a completely new paradigm in context to blockbusters and traditional drugs. Vikram describes these challenges and how pharma leaders can deal with them.
[07:50] Rare diseases are unique; there needs to be a very connected approach for tackling this complexity.
[11:50] How AI/ML is helping solve the patient diagnosis problem.
[15:00] Key takeaways from Vikram’s discussion
KEY TAKEAWAYS:
People suffering from these rare diseases spend between five to seven years before receiving a correct diagnosis. Having a good understanding of the patient journey in rare diseases is critical. Pharma leaders must invest in relevant data sets and build the required infrastructure for new models that leverage AI/ML. Accelerating the speed of diagnosis is a win-win for all.
LINKS MENTIONED:
Vikram Batra on LinkedIn:
BIO:
Vikram is a senior leader in Axtria’s Decision Science practice with over 20 years of analytics, consulting and leadership experience. He has worked on both ends of the spectrum – working for large pharma as well as a long tenure as a management consultant. Vikram has a proven track record of addressing challenging strategic issues for pharmaceutical customers and helping them with comprehensive solutions across brand strategy, sales operations, and market access. He has built, coached and led diverse analytics teams that successfully deliver insights using advanced data analytics and AI. His experience spans across global markets including Top 5 EU, Australia, Canada, and other geographies.
Before joining Axtria, Vikram held roles of increasing responsibility and leadership at MarketRx, Sanofi, Information Resources (IRI) and Health Products Research (HPR).